Abstract:HLA-G is a non-classical HLA class I molecule with immunomodulatory properties. It was initially described at the maternal-fetal interface, and it was later found that this molecule was constitutively expressed on certain immuneprivileged tissues, such as cornea, endothelial and erythroid precursors, and thymus. The immunosuppressive effect of HLA-G is exerted through the interaction with its cognate receptors, expressed on immunocompetent cells, like ILT2, expressed on NK, B, T cells and APCs; ILT4, on APCs; KIR, found on the surface of NK cells; and finally, the co-receptor CD8. Because of these immunomodulatory functions, HLA-G has been involved in several processes, amongst which organ transplantation, viral infections, cancer progression, and autoimmunity. HLA-G neo-expression on tumors has been recently described in several types of malignancies. In fact, tumor progression is tightly linked to the presence of the molecule, as it exerts its tolerogenic function, inhibiting the cells of the immune system and favoring tumor escape. Several polymorphisms in the 3’UTR region condition changes in HLA-G expression (14bp and +3142C/G, among others), which have been associated with both the development and outcome of patients with different tumor types. Also, in recent years, several studies have shown that HLA-G plays an important role in the control of autoimmune diseases. The ability of HLA-G to limit the progression of these diseases has been confirmed and, in fact, levels of the molecule and several of its polymorphisms have been associated with increased susceptibility to the development of autoimmune diseases, as well as increased disease severity. Thus, modulating HLA-G expression in target tissues of oncology patients or patients with autoimmune diseases may be potential therapeutic approaches to treat these pathological conditions.

HLA-G: A New Immune Checkpoint in Cancer?

The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?

HLA-G - evolvement from a trophoblast specific marker to a checkpoint molecule in cancer, a narrative review about the specific role in breast- and gynecological cancer

The HLA-G immune checkpoint: a new immuno-stimulatory role for the α1-domain-deleted isoform

HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies

HLA-G Neo-Expression on Tumors

Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects

HLA-G: Too Much or Too Little? Role in Cancer and Autoimmune Disease

Soluble HLA-G, its diagnostic and prognostic value and potential target molecule for future therapy in cancer

Human leukocyte antigen-G in gynaecological tumours

HLA-G/sHLA-G and HLA-G-Bearing Extracellular Vesicles in Cancers: Potential Role as Biomarkers

Correlation between HLA-G and tumor immunity and its advances

Role of HLA-G in Viral Infections

HLA-G Genotype/Expression/Disease Association Studies: Success, Hurdles, and Perspectives

The importance of HLA-G expression in embryos, trophoblast cells, and embryonic stem cells

Roles of HLA-G/KIR2DL4 in Breast Cancer Immune Microenvironment

[Research progress on HLA-G in non-small cell lung cancer]

Recent Advances in Our Understanding of HLA-G Biology: Lessons from a Wide Spectrum of Human Diseases

HLA-G neo-expression modifies genetic programs governing tumor cell lines

HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevance

HLA-G: An Important Mediator of Maternal-Fetal Immune-Tolerance